TWINSTRAND BIOSCIENCES INC.

In News

U.S. court orders Guardant to pay $245 million in DNA sequencing patent dispute - Reuters

Reuters - Aug 24, 2026

Judge Orders $245M In Guardant Damages In DNA Patent Suit - Law360

Law360 - Aug 24, 2026

TwinStrand Biosciences Announces USPTO Confirmation of Patentability of Core Duplex Sequencing Patent - Business Wire

Business Wire - Nov 05, 2026

Guardant Owes TwinStrand $245 Million, More Patent Royalties (1) - Bloomberg Law News

Bloomberg Law News - Aug 24, 2026

TwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 Patent - Business Wire

Business Wire - Oct 15, 2026

Scantox Acquires DuplexSeq™ Nonclinical Genomics Safety Business from TwinStrand Biosciences - PR Newswire Canada

PR Newswire Canada - Feb 26, 2026

Guardant Fails to Undo $83 Million DNA-Tech Patent Verdict (1) - Bloomberg Law News

Bloomberg Law News - Jun 17, 2026

Guardant Health hit with $83M verdict in TwinStrand DNA sequencing patent lawsuit - Fierce Biotech

Fierce Biotech - Nov 15, 2023

TwinStrand Biosciences and Exact Sciences Announce Exclusive License Agreement for Duplex Sequencing Technology - PR Newswire

PR Newswire - Jul 31, 2024

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment